- No known cause in most patients
- No effective screening
- No reliable early detection mechanism
- For patients diagnosed after its spread: 5-year survival just 2%
- Strikes down women and men equally, and cuts across all races and ethnicities
- Projected to be the 2nd leading cause of cancer death in the U.S. before 2030
- Few tools to combat it (this is beginning to change)
- American Cancer Society estimates for pancreatic cancer in the U.S. (2023):
- 64,050 new cases forecasted in 2023
- 50,550 deaths βabout 70% of patients die within 1 year of diagnosis; 1 in every 13 cancer deaths in the U.S.
- Both the incidence and the mortality figures are still steadily rising!
About Us
The Challenge
Pancreatic Cancer is the deadliest common cancer β with a dismal 5-year survival rate, still just 12%. Here are some of the reasons why:
Our Mission
To increase the 5-year survival rate from 12% to 50% in the next 10 years through early detection and prevention of pancreatic cancer.
Our Current Goal
To raise funds to support The Pancreatic Cancer Early Detection (PRECEDE) Consortium.
PRECEDE is an international, multi-institutional collaborative consortium of world renowned experts in pancreatic cancer. The goal of PRECEDE to increase survival for patients by improving early detection, screening, risk modeling and prevention for those with a heritable risk for pancreatic cancer, through a novel model of collaboration and data sharing. With over 35 leading academic medical centers across the globe, PRECEDE has assembled the largest high-risk patient cohort, with biospecimen collection and longitudinal clinical data.
PRECEDE Consortium
The Pancreatic Cancer Early Detection (PRECEDE) Consortium is an international, multi-institutional collaborative group of experts to increase survival for pancreatic cancer patients by improving early detection, screening, risk modeling and prevention for those with a heritable risk for pancreatic cancer, through a novel model of collaboration and data sharing. PRECEDEβs mission is to transform the early detection and prevention of pancreatic cancer, with the aim of increasing the 5-year survival rate from 12% to 50% within the next 10 years.
With over 30 leading academic medical centers across the globe, PRECEDE has assembled the largest high-risk patient cohort, with longitudinal clinical data and biospecimen acquisition and tracking.
